On a recent episode of CBS Sports Golazo, Clint Dempsey couldn’t resist a dig. Sitting alongside Thierry Henry, Jamie Carragher and Kate Scott, he quipped about Micah Richards’ leaner frame, jokingly crediting Ozempic and christening him “Slim Meeks”.
It was light-hearted, throwaway banter. It was also telling.
Not long ago, a reference like that would have landed awkwardly, if at all. Today, it draws knowing laughter. Weight-loss drugs, once confined to prescriptions and private consultations, are fast becoming part of everyday vocabulary, shorthand for dramatic transformations and whispered explanations for sudden slimness.
The shift is cultural as much as it is clinical. In gyms, offices and group chats, noticeable weight loss increasingly invites a familiar, half-serious question: “Ozempic?” The drug, along with its cousin Wegovy, has moved beyond the realm of medicine into meme, myth and mild accusation.
Nowhere is the phenomenon more visible than in celebrity culture. A raft of Indian public figures, including Karan Johar, Kapil Sharma, Ram Kapoor, Bhumi Pednekar and Kusha Kapila, have found themselves at the centre of speculation over rapid weight loss.
The pattern is familiar: a transformation, followed by social media conjecture, followed by denial. The drug becomes both explanation and insinuation, a compliment edged with scepticism.
This duality sits at the heart of the Ozempic moment. On one hand, these drugs are hailed as breakthroughs, powered by semaglutide, the molecule developed by Novo Nordisk that has reshaped the global obesity conversation. On the other, they carry a whiff of shortcut culture, as though pharmacology were cutting in line ahead of discipline and diet.
That tension may soon be tested in India.
With the patent for semaglutide set to expire locally, domestic pharmaceutical companies are expected to enter the fray with cheaper versions. The implications are significant. Prices could fall sharply, access could widen, and what is currently perceived as an elite or celebrity-adjacent solution could inch closer to the mainstream.
Analysts are already sketching out the contours of that future. Jefferies has described the opportunity as a potential “magic pill” moment for India, projecting a domestic market that could touch $1 billion under the right conditions.
Closer to home, estimates peg the current weight-loss market at around Rs 1,400 crore, with expectations that it could double within a year if affordability improves and supply constraints ease.
The question, then, is not just commercial. It is cultural.
If Ozempic is presently spoken about in hushed tones or coded jokes, what happens when its generic equivalents are as accessible as common lifestyle medications? Does familiarity breed acceptance, or does it simply normalise the suspicion?
There is precedent for both outcomes. Treatments once considered niche or even taboo, from mental health medication to cosmetic procedures, have followed a similar arc from secrecy to social currency.
Yet weight loss occupies a peculiar space, tangled up with ideas of willpower, morality and self-image. A pill that promises to intervene in that equation inevitably invites judgement, even as it gains popularity.
For now, the Ozempic reference sits comfortably in banter, a punchline that lands because everyone is in on the joke. But as the drug, and others like it, become more widely available, the humour may give way to something more ordinary.
And perhaps that is the real inflection point. When a throwaway line on a football show no longer feels like a wink to the audience but simply a reflection of how the world now works.